News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protalex, Inc. (PRTX) Findings From Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthritis



7/26/2012 10:15:37 AM

SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical stage biopharmaceutical company that is developing a class of drugs designed to treat a wide array of autoimmune and inflammatory diseases today announced preliminary findings from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study. The study based in South Africa of PRTX-100 in adult patients with active rheumatoid arthritis (RA) demonstrated that PRTX-100 was generally safe and well tolerated in patients with active RA at all dose levels.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES